235O Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.229 ◽

2020 ◽

Vol 31 ◽

pp. S1335

Author(s):

X. Wu ◽

J. Zhu ◽

R. Yin ◽

J. Yang ◽

J. Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Chinese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

Starting Dose

Download Full-text

LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2259 ◽

2020 ◽

Vol 31 ◽

pp. S1160-S1161

Author(s):

X. Wu ◽

J. Zhu ◽

R. Yin ◽

J. Yang ◽

J. Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Chinese Patients ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

Starting Dose

Download Full-text

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Annals of Oncology ◽

10.1016/j.annonc.2020.12.018 ◽

2021 ◽

Author(s):

X.H. Wu ◽

J.Q. Zhu ◽

R.T. Yin ◽

J.X. Yang ◽

J.H. Liu ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive ◽

Starting Dose

Download Full-text

Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5504 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5504-5504 ◽

Cited By ~ 3

Author(s):

Christian Kurzeder ◽

Isabel Bover ◽

Frederik Marmé ◽

Joern Rau ◽

Patricia Pautier ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Resistant

Download Full-text

Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00752-6 ◽

2021 ◽

Vol 162 ◽

pp. S57-S58

Author(s):

Ning Li ◽

Youzhong Zhang ◽

Jing Wang ◽

Jianqing Zhu ◽

Li Wang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Sensitive

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2261 ◽

2020 ◽

Vol 31 ◽

pp. S1161-S1162 ◽

Cited By ~ 1

Author(s):

K.N. Moore ◽

M. Bookman ◽

J. Sehouli ◽

A. Miller ◽

C. Anderson ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Stage Iii ◽

Newly Diagnosed ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Yearbook of Medicine ◽

10.1016/s0084-3873(09)79327-7 ◽

2009 ◽

Vol 2009 ◽

pp. 63-64

Author(s):

B. Hutton

Keyword(s):

Ankylosing Spondylitis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

MUltiple Sclerosis and Extract of Cannabis (MUSEC): a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis (MS)

http://isrctn.org/> ◽

10.1186/isrctn42223114 ◽

2012 ◽

Author(s):

John Zajicek

Keyword(s):

Multiple Sclerosis ◽

Cannabis Sativa ◽

Symptomatic Relief ◽

Muscle Stiffness ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text